05/08/2024 15:00 |
StemRIM Announces Setting the Record Date for Extraordinary General Meeting of Shareholders , and Reduction of Capital Stock (Capital Decrease) |
03/21/2024 15:30 |
StemRIM Announces Symposium on "Regeneration-Inducing Medicine" at the 23rd Congress of the Japanese Society for Regenerative Medicine |
03/15/2024 16:00 |
Presentation Materials for the Six Months Ended January 31, 2024 |
03/13/2024 15:30 |
StemRIM Announces Initiation of Phase 2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy |
03/13/2024 15:30 |
Non-consolidated Financial Results for the Six Months Ended January 31, 2024[Japanese GAAP] |
02/29/2024 16:00 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborators |
02/15/2024 15:00 |
StemRIM Announces Patent Registration (Japan) for the Use of Redasemtide, as a Therapeutic Indication of Therapeutic Medication for Cartilage Disorder |
02/14/2024 15:30 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborators |
01/31/2024 16:00 |
StemRIM Announces Patent Registration (Russia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders |
12/28/2023 16:00 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to External Collaborator |
12/13/2023 15:00 |
StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to External Collaborator |
12/13/2023 15:00 |
Non-consolidated Financial Results for the Three Months Ended October 31, 2023[Japanese GAAP] |
12/06/2023 17:35 |
StemRIM Announces Completion of Payment for Issuance of New Shares as Restricted Stock Compensation |
12/04/2023 15:00 |
StemRIM Announces Conclusion of Agreement for the Initiation of a Phase2 Clinical Trial for Redasemtide in Ischemic Cardiomyopathy |
11/16/2023 11:00 |
[Delayed]StemRIM Announces Issuance of New Shares as Remuneration for Restricted Stock |
11/16/2023 11:00 |
[Delayed]StemRIM Announces Extension of the Tripartite Collaborative Research Agreement Updated on January 24, 2023 |
10/27/2023 16:45 |
[Delayed]StemRIM Announces Change of Representative Directors |
09/28/2023 16:00 |
StemRIM Announces Fixed Details of the Issuance of Stock Options to Temporary Employee and External collaborator |
09/28/2023 14:15 |
[Delayed]StemRIM Announces Proposal for Approval of Issuance of Stock Options to our Executive Officers, Employees, and External Collaborators |
09/20/2023 11:00 |
[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Employee |
09/20/2023 11:00 |
[Delayed]StemRIM Announces Fixed Details of the Issuance of Stock Options to Director |
09/19/2023 17:00 |
[Delayed]Presentation Material, Financial Results for the Fiscal Year Ended July 31, 2023 |
09/19/2023 10:30 |
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Temporary Employee and External collaborator |
09/19/2023 10:30 |
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Employee |
09/19/2023 10:30 |
[Delayed]StemRIM Announces Issuance of Stock Acquisition Rights as Stock Options to Director |
09/13/2023 15:30 |
Non-consolidated Financial Results for the Fiscal Year Ended July 31, 2023 [Japanese GAAP] |
09/06/2023 15:00 |
StemRIM Announces Patent Registration (US) for the Use of Redasemtide as an Additional Therapeutic Indication for Cardiomyopathy |
09/04/2023 15:00 |
StemRIM Announces Patent Registration (China) for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction |
07/31/2023 16:00 |
StemRIM Announces the First Administration of Global Late Phase 2 Clinical Trials for Redasemtide Targeting Acute Ischemic Stroke (Japan) |
07/25/2023 17:00 |
StemRIM Announces the Initiation of Global Late Phase 2 Clinical Trials for Redasemtide (HMGB1 Peptide) Targeting Acute Ischemic Stroke (Europe, China |
07/18/2023 15:00 |
Notice of Patent Registration (Korea) for Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction |
06/19/2023 11:30 |
[Delayed]Non-consolidated Financial Results for the Nine Months Ended April 30, 2023[Japanese GAAP] |
06/01/2023 17:30 |
StemRIM Announces Exhibiting at the "BIO International Convention 2023" and Participating in the "Jefferies 2023 Global Healthcare Conference New York |
05/24/2023 17:30 |
StemRIM Announces Orphan Drug Designation of Regeneration-Inducing Medicine Redasemtide (HMGB1 peptide) |
05/22/2023 17:30 |
StemRIM Announces Results from Phase 2 Clinical Trial of Redasemtide in Patients with Chronic Liver Disease (Additional Report) |